Key result
MAFLD is not independently linked to depression, anxiety, or cardiovascular parameters after multivariate adjustment.
Why the study?
The relationship between anxiety and depression in metabolic-dysfunction-associated fatty liver disease (MAFLD) and cardiovascular risk remained uncertain.
Are anxiety and depression associated with increased cardiovascular risk parameters in patients with MAFLD?
Cross-Sectional (n=77)
Are anxiety and depression associated with increased cardiovascular risk parameters in patients with MAFLD?
p-value: p=0.009
While anxiety and depression scores are elevated in MAFLD patients, their association with echocardiographic markers of cardiovascular risk is not independent of other factors.
Anxiety and depression scores in MAFLD are not independently linked to cardiovascular parameters; leaves open psychological contributions beyond confounders.
(1) Background: The relationship between anxiety and depression in metabolic-dysfunction-associated fatty liver disease (MAFLD) and cardiovascular (CV) risk remains uncertain. Therefore, we aimed to assess whether anxiety and depression are associated with increased CV risk in MAFLD. (2) Methods: We conducted a cross-sectional observational study involving 77 subjects (39 MAFLD patients, 38 controls), between January and September 2020. Hepatic steatosis was assessed using a combination of hepatic ultrasonography and SteatoTestTM. CV parameters were evaluated using echocardiography and Doppler ultrasound. Self-reported questionnaires pertaining to symptoms of anxiety and depression were used. Anxiety was evaluated using Lehrer Woolfolk Anxiety Symptom Questionnaire (LWASQ), further divided into somatic, behavioral, and cognitive factors, as well as a global score, and depression using Beck Depression Inventory (BDI). (3) Results: MAFLD patients presented significantly higher BDI scores (p-value 0.009) and LWASQ global scores (p-value 0.045) than controls. LWASQ somatic factor was significantly associated with global longitudinal strain (GLS) in linear analysis (−0.0404, p-value = 0.002), while it lost significance following multivariate analysis (−0.0166, p-value = 0.124). Although group (MAFLD vs. controls) predicted BDI, LWASQ global score, and LWASQ somatic factor in linear regression, they lost significance in multivariate analysis. Moreover, the relationship between interventricular septal wall thickness (IVSWT) and BDI, LWASQ global score, and LWASQ somatic factor was significant in linear analysis, but statistical significance disappeared after multivariate analysis. (4) Conclusions: Although MAFLD patients presented increased anxiety and depression risk in univariate analysis, this association lost significance in multivariate analysis. A significant association between GLS levels and LWASQ somatic factor, in addition to IVSWT in anxiety and depression in univariate analysis, was observed, but was lost after multivariate analysis.
No takes yet. Share an insight, caveat, or question.
Ismaiel et al. (2022) conducted a cross-sectional in Metabolic-dysfunction-associated fatty liver disease (MAFLD) (n=77). Metabolic-dysfunction-associated fatty liver disease (MAFLD) vs. Controls was evaluated on Anxiety (LWASQ) and depression (BDI) scores and their association with cardiovascular parameters (p=0.009). MAFLD patients had higher depression (p=0.009) and anxiety (p=0.045) scores than controls, but these associations and their links to cardiovascular parameters lost significance in multivariate analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: